NVO - Obesity Drug Landscape Has A Contender From Biohaven CEO Highlights Different Approach Amid Stiff Competition From Novo Nordisk Eli Lilly | Benzinga
Monday, Biohaven’s (NYSE:BHVN) CEO, Vlad Coric, joined CNBC Fast Money to discuss the weight loss drug wars and the company’s experimental obesity drug.
Biohaven said it is developing an obesity drug that works differently from Novo Nordisk A/S’s (NYSE:NVO) and Eli Lilly And Co’s (NYSE:LLY) popular GLP-1 drugs.
The experimental obesity drug, dubbed taldefgrobep alfa (BHVN-2000), could prevent muscle loss while helping shed weight.
The company highlights that 20%-50% of the weight loss with GLP-1 drugs is actually muscle mass.
“What we are trying to do is result in significant weight loss without losing muscle mass, which is what we see with the GLPs,” CEO Vlad Coric told CNBC.
So Biohaven is developing taldefgrobep alfa (t-alpha) and targets myostatin, which regulates muscle growth.
Coric added, “While blocking myostatin, ...